Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
1.580
-0.070 (-4.24%)
At close: Mar 28, 2025, 4:00 PM
1.630
+0.050 (3.16%)
After-hours: Mar 28, 2025, 7:07 PM EST
Armata Pharmaceuticals Revenue
In the year 2024, Armata Pharmaceuticals had annual revenue of $5.17M with 14.24% growth. Armata Pharmaceuticals had revenue of $1.24M in the quarter ending December 31, 2024, a decrease of -19.18%.
Revenue (ttm)
$5.17M
Revenue Growth
+14.24%
P/S Ratio
11.04
Revenue / Employee
$78,394
Employees
66
Market Cap
57.17M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ARMP News
- 10 days ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PRNewsWire
- 18 days ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire
- 20 days ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 7th Annual Bacteriophage Therapy Summit - PRNewsWire
- 3 months ago - Armata Pharmaceuticals Announces Encouraging Results from the Phase 2 Tailwind Study of Inhaled AP-PA02 in Non-Cystic Fibrosis Bronchiectasis Subjects with Chronic Pulmonary Pseudomonas aeruginosa Infection - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces that CEO Dr. Deborah Birx Will Deliver a Presentation at the 5th Annual Phage Futures Annual Meeting - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces Third Quarter 2024 Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Armata Pharmaceuticals Announces the Completion of Enrollment of its Phase 1b/2a diSArm Study Evaluating Intravenous AP-SA02 as a Potential Treatment for Staphylococcus aureus Bacteremia - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Structural Biology Publication - PRNewsWire